Restoring AIBP expression in the retina provides neuroprotection in glaucoma
- PMID: 40349106
- PMCID: PMC12461634
- DOI: 10.1016/j.ymthe.2025.05.009
Restoring AIBP expression in the retina provides neuroprotection in glaucoma
Abstract
Glaucoma is a neurodegenerative disease manifested by retinal ganglion cell (RGC) death and irreversible blindness. We have identified apolipoprotein A-I binding protein (AIBP) that controls excessive cholesterol accumulation and neuroinflammation in the retina by upregulating the cholesterol transporter ABCA1 and reducing TLR4 signaling and mitochondrial dysfunction. Here, we demonstrated that AIBP and ABCA1 expression were decreased, whereas Toll-like receptor 4 (TLR4), interleukin-1β (IL-1β), and the cholesterol content increased in the retina of patients with glaucoma and mouse models of glaucoma. Restoring AIBP deficiency by a single intravitreal injection of adeno-associated virus (AAV) protected RGCs and ameliorated visual dysfunction in experimental glaucoma. Conversely, AAV-mediated RGC-specific AIBP knockdown exacerbated RGC loss and visual dysfunction in a mouse model of glaucoma. Mechanistically, AAV-AIBP attenuated TLR4 and IL-1β expression and localization of TLR4 to lipid rafts, reduced cholesterol accumulation, and ameliorated visual dysfunction. Additionally, AAV-AIBP promoted mitochondrial complexity and function in Müller glia in vivo. Recombinant AIBP protein inhibited TLR4 and IL-1β activation and alleviated mitochondrial dysfunction in Müller glia in response to elevated pressure in vitro. These studies indicate that restoring AIBP expression in the glaucomatous retina reduces neuroinflammation and protects RGCs and Müller glia, suggesting the therapeutic potential of AAV-AIBP in human glaucoma.
Keywords: AAV; AIBP; Müller glia; RGC; TLR4; cholesterol; glaucoma; mitochondria; neuroinflammation; neuroprotection.
Copyright © 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests W.K.J., S.H.C., and Y.I.M. are co-inventors named on patents and patent applications by the University of California, San Diego. Y.I.M. is a scientific co-founder of Raft Pharmaceuticals LLC. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Other authors declare no competing interests.
Update of
-
Restoring AIBP expression in the retina provides neuroprotection in glaucoma.bioRxiv [Preprint]. 2023 Dec 29:2023.10.16.562633. doi: 10.1101/2023.10.16.562633. bioRxiv. 2023. Update in: Mol Ther. 2025 Aug 6;33(8):3841-3862. doi: 10.1016/j.ymthe.2025.05.009. PMID: 37905114 Free PMC article. Updated. Preprint.
References
-
- Navarro-Partida J., Martinez-Rizo A.B., Ramirez-Barrera P., Velazquez-Fernandez J.B., Mondragon-Jaimes V.A., Santos-Garcia A., Benites-Godinez V. Association of Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk of primary open angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 2017;255:995–1001. doi: 10.1007/s00417-017-3610-4. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
